Enzymatica AB (publ) (FRA:EN9)

Market Cap	54.77M -19.4%
Revenue (ttm)	4.84M +9.6%
Net Income	-4.31M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1775
Previous Close	0.1810
Day's Range	0.1775 - 0.1775
52-Week Range	0.1220 - 0.2800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 16, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EN9

Financial Performance

In 2025, Enzymatica AB's revenue was 53.90 million, an increase of 18.27% compared to the previous year's 45.58 million. Losses were -51.89 million, -2.42% less than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error